argenx (NASDAQ:ARGX) Reaches New 52-Week High at $423.99

argenx SE (NASDAQ:ARGX – Get Rating) shares reached a new 52-week high on Monday . The company traded as high as $423.99 and last traded at $423.25, with a volume of 32473 shares. The stock had previously closed at $422.58.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ARGX. Bank of America lifted their price target on shares of argenx from $444.00 to $446.00 in a research note on Friday, May 5th. SVB Leerink boosted their target price on shares of argenx from $430.00 to $435.00 and gave the company an “outperform” rating in a research note on Friday, March 3rd. Truist Financial boosted their target price on shares of argenx from $420.00 to $440.00 in a research note on Friday, May 5th. Piper Sandler boosted their target price on shares of argenx from $465.00 to $475.00 and gave the company an “overweight” rating in a research note on Thursday, February 23rd. Finally, HC Wainwright boosted their target price on shares of argenx from $182.00 to $494.00 in a research note on Friday, May 5th. One analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $454.24.

argenx Trading Down 1.4 %

The stock has a market capitalization of $23.03 billion, a P/E ratio of -44.52 and a beta of 0.75. The company has a fifty day simple moving average of $384.69 and a two-hundred day simple moving average of $378.48.

argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings data on Thursday, March 2nd. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($3.08) by $2.38. The firm had revenue of $182.12 million during the quarter, compared to analysts’ expectations of $177.11 million. argenx had a negative return on equity of 35.36% and a negative net margin of 79.45%. As a group, analysts forecast that argenx SE will post -6.33 earnings per share for the current fiscal year.

Institutional Trading of argenx

Hedge funds have recently modified their holdings of the company. USS Investment Management Ltd acquired a new stake in shares of argenx in the 3rd quarter valued at approximately $3,542,000. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of argenx by 29.5% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 803 shares of the company’s stock valued at $304,000 after acquiring an additional 183 shares during the period. Parallel Advisors LLC raised its position in shares of argenx by 9.4% in the 4th quarter. Parallel Advisors LLC now owns 430 shares of the company’s stock valued at $163,000 after acquiring an additional 37 shares during the period. Aigen Investment Management LP acquired a new stake in shares of argenx in the 3rd quarter valued at approximately $1,972,000. Finally, Eaton Vance Management raised its position in shares of argenx by 0.4% in the 3rd quarter. Eaton Vance Management now owns 348,522 shares of the company’s stock valued at $123,046,000 after acquiring an additional 1,394 shares during the period. 57.29% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

(Get Rating)

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.